Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells
- aEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114;
- bDepartment of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138; and
- cCenter for Regenerative Medicine, Richard B. Simches Research Center, Massachusetts General Hospital, Boston, MA 02114
See allHide authors and affiliations
Contributed by Rakesh K. Jain, June 6, 2013 (sent for review February 1, 2013)

Abstract
Efficient generation of competent vasculogenic cells is a critical challenge of human induced pluripotent stem (hiPS) cell-based regenerative medicine. Biologically relevant systems to assess functionality of the engineered vessels in vivo are equally important for such development. Here, we report a unique approach for the derivation of endothelial precursor cells from hiPS cells using a triple combination of selection markers—CD34, neuropilin 1, and human kinase insert domain-containing receptor—and an efficient 2D culture system for hiPS cell-derived endothelial precursor cell expansion. With these methods, we successfully generated endothelial cells (ECs) from hiPS cells obtained from healthy donors and formed stable functional blood vessels in vivo, lasting for 280 d in mice. In addition, we developed an approach to generate mesenchymal precursor cells (MPCs) from hiPS cells in parallel. Moreover, we successfully generated functional blood vessels in vivo using these ECs and MPCs derived from the same hiPS cell line. These data provide proof of the principle that autologous hiPS cell-derived vascular precursors can be used for in vivo applications, once safety and immunological issues of hiPS-based cellular therapy have been resolved. Additionally, the durability of hiPS-derived blood vessels in vivo demonstrates a potential translation of this approach in long-term vascularization for tissue engineering and treatment of vascular diseases. Of note, we have also successfully generated ECs and MPCs from type 1 diabetic patient-derived hiPS cell lines and use them to generate blood vessels in vivo, which is an important milestone toward clinical translation of this approach.
Footnotes
↵1Present address: Centre for Stem Cell Research, Christian Medical College, Bagayam, Vellore 632002, Tamil Nadu, India.
↵2R. Samuel, L.D., S.L., and T.V. contributed equally to this work.
↵3Present address: Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305.
↵4Present address: Office of Cellular, Tissue, and Gene Therapies, US Food and Drug Administration, Rockville, MD 20852.
- ↵5To whom correspondence may be addressed. E-mail: dai{at}steele.mgh.harvard.edu or jain{at}steele.mgh.harvard.edu.
Author contributions: R. Samuel, D.G.D., D.F., and R.K.J. designed research; R. Samuel, S.L., T.V., W.S.K., A.B., C.B., R. Schäfer, and X.H. performed research; R. Samuel, L.D., S.L., T.V., W.S.K., A.B., P.A., D.T.S., D.G.D., D.F., and R.K.J. analyzed data; and R. Samuel, D.G.D., D.F., and R.K.J. wrote the paper.
Conflict of interest statement: R.K.J. received research grants from Dyax, MedImmune, and Roche; received consultant fees from Enlight, Noxxon, SynDevRx, WebMD, and Zyngenia; owns equity in Enlight, SynDevRx, and XTuit; and serves on the Board of Directors of XTuit and the Board of Trustees of H&Q Healthcare Investors and H&Q Life Sciences Investors. No reagents or funding from these companies was used in these studies; therefore, there is no significant financial or other competing interest in the work.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1310675110/-/DCSupplemental.
Freely available online through the PNAS open access option.